3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
122
Thoracic
10
Gastrointestinal
10
Gynecologic
9
Genitourinary
8
Head & Neck
6
Other solid neoplasm
4
Dermatologic
4
Sarcoma
3
Endocrine
2
CNS
2
NET
1
Lymphoid
1
Conditions
Neuroendocrine Tumors
70
Carcinoma, Neuroendocrine
7
Gastro-enteropancreatic neuroendocrine tumor
6
Carcinoid Tumor
6
Neoplasm Metastasis
5
Paraganglioma
3
Pancreatic Neoplasms
3
Carcinoma, Hepatocellular
3
Adenoma, Islet Cell
3
Thyroid Neoplasms
2
Stomach Neoplasms
2
Sarcoma
2
Neoplasms
2
Lung Neoplasms
2
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Tertiary Lymphoid Structures
1
Teratoma
1
Small Intestinal Neuroendocrine Tumor
1
Small Cell Lung Carcinoma
1
Rectal Neuroendocrine Tumor
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Parkinson Disease
1
Pancreatic Neuroendocrine Tumors in MEN1
1
Osteomalacia
1
Neuroendocrine Tumors With Metastasis
1
Neuroendocrine Tumors Metastatic to the Liver
1
Neuroendocrine Tumor Grade 3
1
Neuroblastoma
1
Interventions
regorafenib
1
Clinical Trials, Phase II as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Triple Negative Breast Neoplasms
×
NET
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled